摘要
观察以去甲长春碱为主的联合化疗治疗晚期恶性肿瘤的疗效和安全性。４５例晚期肿瘤患者接受以去甲长春碱（Ｖｉｎｏｒｅｌｂｉｎｅ）为主的联合化疗，其中非小细胞肺癌２４例，乳腺癌１１例，恶性淋巴瘤１０例。非小细胞肺癌的化疗方案为ＮＰ、ＮＥＰ和ＭＮＰ，乳腺癌为ＮＦ和ＮＡＦ，恶性淋巴瘤为ＣＨＮＰ和ＭＩＮＥ。４５例患者可评价疗效和毒性。白细胞减少Ⅰ～Ⅳ度发生率为８２．２％（按病例数）和６０．８％（按周期数），Ⅲ～Ⅳ度减少分别为２８．９％和１４．４％。血小板减少和血红蛋白减少少见。其它毒性反应有脱发（２８．９％），恶心、呕吐（２２．２％），而神经毒性并不常见。总有效率６２．２％（ＣＲ１０例，ＰＲ１８例）。非小细胞肺癌、乳腺癌和恶性淋巴瘤有效率分别为５０．０％，５４．５％和１００．０％。本组观察提示，去甲长春碱联合化疗治疗非小细胞肺癌，乳腺癌和恶性淋巴瘤有效，且可耐受。ＭＮＰ方案对非小细胞肺癌及ＭＩＮＥ方案对复发或难治性恶性淋巴瘤的疗效。
To evaluate efficacy and safety profile of vinorelbine based combination in the treatment of advanced malignancies.From October 1995 to January 1997,forty five patients received vinorelbine based chemotherapy.Of 45 patients,24 were non small cell lung cancer(NSCLC),11 breast cancer,10 non Hodgkin's lymphoma(NHL).Forty five patients were evaluated.Leukopenia occurred in 82.2% of patients and 60.8% of cycles.Thrombopenia and anemia were uncommon.Other frequent side effects were alopecia(28.9%),nausea and vomiting(22.2%).Neurotoxicity was infrequent.The overall response rate for 45 patients was 62.2%,with ten complete response(CR) and 18 partial response(PR).54.5% response rate in breast cancer,50.0% in NSCLC and 100.0% in NHL. This study shows that vinorelbine based combination was active and tolerable in the treatment of NSCLC,breast cancer and NHL;meanwile MNP regimen was active in advanced NSCLC and MINE regimen was more effective in recurrent and refectory NHL.
出处
《实用肿瘤杂志》
CAS
北大核心
1998年第2期79-82,共4页
Journal of Practical Oncology
